Increased Hemorrhage During Excision of Bevacizumab‐Treated <scp>NF2</scp> ‐Related Vestibular Schwannomas

ABSTRACT Objectives To determine if the chronic use of bevacizumab, prior to withholding for elective surgery in the preoperative period, increases the risk of hemorrhage during vestibular schwannoma (VS) resections. Methods Retrospective reviews of estimated intraoperative blood loss volume during surgical resection of 50 bevacizumab‐treated and 56 bevacizumab‐untreated VS from patients with NF2 ‐related schwannomatosis ( NF2 ‐SWN). Two index cases are included. Additionally, masked histopathologic examination of tissues from bevacizumab‐treated and untreated VS was evaluated. Results The mean blood loss during VS resection was statistically increased in patients with prior bevacizumab treatment (421 mL) compared to untreated patients (285 mL) ( p = 0.015). When accounting for both tumor size and the amount of tumor resected, blood loss per percent of tumor resected was also elevated in the bevacizumab treated group (15.78 mL/%resection) when compared to the untreated group (12.97 mL/%resection) ( p = 0.024). Intraoperative hemostasis using standard techniques was difficult, and some cases resulted in early termination of the surgical procedure prior to total resection. Eighteen percent of bevacizumab‐treated patients had gross total or near total tumor resection, while untreated tumors had 52% gross total or near total resections ( p ‐value = 0.001). The length of time on bevacizumab preoperatively correlated with intraoperative blood loss ( p = 0.049). The median time patients were treated with bevacizumab prior to surgery was 23.5 months and ranged from 3 to 121 months. The median time off bevacizumab prior to surgery was 11.5 months and ranged from 0.75 to 87 months. Histopathologic examination revealed no readily apparent difference in blood vessel density, integrity, or growth patterns. Conclusions Bevacizumab treatment prior to excision of NF2 ‐SWN VS in this retrospective case series is associated with increased intraoperative hemorrhage. Bleeding was difficult to control using standard techniques, thus warranting preoperative surgical awareness. Underlying pathologic mechanisms are not yet understood and are under further investigation. Level of Evidence 3.

Authors

Institutions

Publication Details

Journal
The Laryngoscope
Published
2025-06-13
DOI
https://doi.org/10.1002/lary.32342
Citations
2
Primary Topic
Neurofibromatosis and Schwannoma Cases
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Increased Hemorrhage During Excision of Bevacizumab‐Treated NF2 ‐Related Vestibular Schwannomas

Bob S. Carter, Christopher G. Wood, D. Bradley Welling, Liana Kozanno et al.
2 citations
The Laryngoscope
Neurofibromatosis and Schwannoma Cases
2.78
article

Increased Hemorrhage During Excision of Bevacizumab‐Treated NF2 ‐Related Vestibular Schwannomas

Bob S. Carter, Christopher G. Wood, D. Bradley Welling, Liana Kozanno, Justin T. Jordan, Scott Randall Plotkin, Long‐Sheng Chang, Anat Stemmer‐Rachamimov, Daniel J. Lee, Fred G. Barker
article en
2 citations

Abstract

ABSTRACT Objectives To determine if the chronic use of bevacizumab, prior to withholding for elective surgery in the preoperative period, increases the risk of hemorrhage during vestibular schwannoma (VS) resections. Methods Retrospective reviews of estimated intraoperative blood loss volume during surgical resection of 50 bevacizumab‐treated and 56 bevacizumab‐untreated VS from patients with NF2 ‐related schwannomatosis ( NF2 ‐SWN). Two index cases are included. Additionally, masked histopathologic examination of tissues from bevacizumab‐treated and untreated VS was evaluated. Results The mean blood loss during VS resection was statistically increased in patients with prior bevacizumab treatment (421 mL) compared to untreated patients (285 mL) ( p = 0.015). When accounting for both tumor size and the amount of tumor resected, blood loss per percent of tumor resected was also elevated in the bevacizumab treated group (15.78 mL/%resection) when compared to the untreated group (12.97 mL/%resection) ( p = 0.024). Intraoperative hemostasis using standard techniques was difficult, and some cases resulted in early termination of the surgical procedure prior to total resection. Eighteen percent of bevacizumab‐treated patients had gross total or near total tumor resection, while untreated tumors had 52% gross total or near total resections ( p ‐value = 0.001). The length of time on bevacizumab preoperatively correlated with intraoperative blood loss ( p = 0.049). The median time patients were treated with bevacizumab prior to surgery was 23.5 months and ranged from 3 to 121 months. The median time off bevacizumab prior to surgery was 11.5 months and ranged from 0.75 to 87 months. Histopathologic examination revealed no readily apparent difference in blood vessel density, integrity, or growth patterns. Conclusions Bevacizumab treatment prior to excision of NF2 ‐SWN VS in this retrospective case series is associated with increased intraoperative hemorrhage. Bleeding was difficult to control using standard techniques, thus warranting preoperative surgical awareness. Underlying pathologic mechanisms are not yet understood and are under further investigation. Level of Evidence 3.

The LaryngoscopeVol. 135(11)
Massachusetts Eye and Ear Infirmary (US), Nationwide Children's Hospital (US), Harvard University (US), Massachusetts General Hospital (US), The Ohio State University (US)
Openalex Percentile: Top 10%
Neurofibromatosis and Schwannoma Cases
2.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.